-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Tempus AI reported Q1 2026 revenue of $348.1M (+36.1% Y/Y), beating the $345M consensus as both Diagnostics ($261.1M, +34.7%) and Data & Applications ($87.0M, +40.5%) segments delivered robust growth. Adjusted EPS of ($0.13) significantly outperformed the ($0.20) consensus and ($0.24) prior year result, while adjusted EBITDA improved $13.3M to ($2.8M) and adjusted gross margin reached 65.0% (up 360 bps Y/Y). Strong volume growth included 28% in Oncology testing, 54% in Hereditary following the Ambry Genetics acquisition in Q1 2025 (7% organic), and 500% in MRD testing to 6,500 tests performed. Following the strong beat, TEM raised 2026 revenue guidance to $1.59B-$1.60B (approximately 25% growth) while maintaining adjusted EBITDA guidance of $65M. We believe TEM's first Investor Day scheduled for May 29, 2026 should provide additional insights on market dynamics and long-term growth expectations, supporting the company's trajectory toward sustained profitability.